Ahmad Awada

25PUBLICATIONS
123CO-AUTHORS
Molecular targetsMedical biotechnology diagnostics (incl. biosensors)Predictive and prognostic markersGlycoconjugatesCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Nov 26, 2025
Palbociclib and endocrine therapy diminish adaptive anti-tumor immunity in early breast cancer: The NeoRHEA phase 2 study.

Andreas Papagiannis, Samira Majjaj, Francois P Duhoux

|Oct 10, 2024
Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer.

Eric Van Cutsem, Joelle Collignon, Rikke L Eefsen

|Jul 27, 2024
Correction: Krayem et al. Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. Cancers 2020, 12, 512.

Mohammad Krayem, Philippe Aftimos, Ahmad Najem

|Oct 25, 2023
Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium.

Mariana Brandão, Diogo Martins-Branco, Claudia De Angelis

|Jul 29, 2023
Targeting Prohibitins to Inhibit Melanoma Growth and Overcome Resistance to Targeted Therapies.

Ahmad Najem, Mohammad Krayem, Serena Sabbah

|Jul 12, 2023
Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment.

Guilherme Nader-Marta, Chiara Molinelli, Véronique Debien

Pageof 5

Frequent Collaborators

5 joint publications

Mohammad Krayem

4 joint publications

Francois P Duhoux

4 joint publications

Evandro de Azambuja

4 joint publications

Ahmad Najem